CSL Behring exists to meet the needs of patients with rare and serious diseases, and those suffering from trauma-related bleeding. Plasma-derived therapies (PDTs) form the core of the portfolio. Patients are the core focus. CSL Behring consists of three vertically integrated components that span the journey from donor to patient. In plasma collection the focus is on three areas; enhancing collection efficiency, reducing the unit acquisition cost and providing a world-class experience for donors and communities. CSL Behring’s manufacturing capability is focused on: • fractionating and transforming plasma into a portfolio of innovative PDTs, and • delivering supply of CSL’s recombinant medicines. CSL Behring’s commercial and medical teams around the world are engaged with healthcare providers, payers and key stakeholders, working to meet patient needs and to deliver successful launches of CSL’s life-saving therapies. This helps provide access to more people with rare and serious diseases. One of CSL Behring’s key priorities is sourcing sufficient and sustainable volumes of plasma to meet the growing need for CSL’s medicines. PDTs have a 9–12 month manufacturing cycle, which is more complex than other pharmaceutical products. These products are vital for patients in need, and can transform their lives. CSL Behring commits to reducing the cost per litre of plasma. The aim to increase yield for immunoglobulins (Ig) and albumin through data analytics, smarter plasma allocation and implementing an operational excellence program. In plasma collection, the Rika collection device and individualised nomogram, iNomi™, enables CSL to collect the optimal amount of plasma from donors. These avenues to yield improvement through technology and innovation are critical to CSL’s ability to increase the supply of therapies to patients. There is significant opportunity for continued global immunoglobulin (lg) growth as the market expands. Within this growing market, PRIVIGEN® and HIZENTRA® are expected to gain share. CSL Behring plays a leading role in Ig and will continue to identify expansion opportunities. CSL expects the global haemophilia B market to grow in coming years due to the steady prevalence of the disease and the launch of novel treatments, including gene therapies. As this market grows, CSL Behring will look to expand its portfolio. The hereditary angioedema (HAE) market may also grow due to improved diagnosis rates and new prophylaxis therapies. ANDEMBRY® (garadacimab), CSL’s next generation HAE therapy, is now approved in US, European Union (EU), United Kingdom (UK), Japan, Switzerland, Australia and the United Arab Emirates. It is available in US, Japan, Germany and Greece. CSL Behring has built on its leadership position and continues to innovate across rare and serious diseases. + READ MORE AT INVESTORS.CSL.COM CSL’s Businesses and Outlook US$11,158m CSL Behring revenue 16 Performance
RkJQdWJsaXNoZXIy MjE2NDg3